198 related articles for article (PubMed ID: 6222117)
21. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
23. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
24. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.
Brown EJ; Joiner KA; Gaither TA; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):409-15. PubMed ID: 6223077
[TBL] [Abstract][Full Text] [Related]
25. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
26. Formation of high affinity C5 convertase of the classical pathway of complement.
Rawal N; Pangburn MK
J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586
[TBL] [Abstract][Full Text] [Related]
27. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
Asghar SS; de Koster A; van der Helm HJ
Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
[TBL] [Abstract][Full Text] [Related]
28. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
Sobel AT; Cooper NR; Schreiber RD
J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
[TBL] [Abstract][Full Text] [Related]
29. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
30. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
Strunk RC; Webster RO
Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
[TBL] [Abstract][Full Text] [Related]
32. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
Ezzell JL; Parker CJ
Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
[TBL] [Abstract][Full Text] [Related]
33. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
34. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
35. Regulation of the alternative pathway of human complement by C1q.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1987 Sep; 24(9):987-93. PubMed ID: 2958692
[TBL] [Abstract][Full Text] [Related]
36. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme.
Rawal N; Pangburn MK
J Biol Chem; 1998 Jul; 273(27):16828-35. PubMed ID: 9642242
[TBL] [Abstract][Full Text] [Related]
37. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
38. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
39. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
40. Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.
Devine DV; Rosse WF
Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5873-7. PubMed ID: 2956607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
